Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .

Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA.

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody.

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.

Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.

Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis.